Embecta BD U-500 insulin syringe
The U-500 insulin delivery syringe. The FDA’s warning does not affect syringes like this one made by Embecta. [Image from Embecta/BD]

Embecta (Nasdaq:EMBC) says an FDA safety communication regarding certain plastic syringes has no impact on its own products.

The FDA yesterday warned of the potential for device failures with plastic syringes manufactured in China. Failures could include leaks, breakage and other problems. The agency said it received information about quality issues associated with several Chinese syringe manufacturers.

Embecta, the BD diabetes business spinoff, manufactures syringe devices for the delivery of insulin. However, the manufacturing for these devices only takes place in the U.S.

Get the full story at our sister site, Drug Delivery Business News.